{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:27:00Z","timestamp":1772515620073,"version":"3.50.1"},"reference-count":53,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The use of Natalizumab in Multiple Sclerosis (MS) can cause the reactivation of the polyomavirus JC (JCPyV); this may result in the development of progressive multifocal leukoencephalopathy (PML), a rare and usually lethal disease. JCPyV infection is highly prevalent in worldwide population, but the detection of anti-JCPyV antibodies is not sufficient to identify JCPyV infection, as PML can develop even in patients with negative JCPyV serology. Better comprehension of the JCPyV biology could allow a better understanding of JCPyV infection and reactivation, possibly reducing the risk of developing PML. Here, we investigated whether JCPyV miR-J1-5p\u2014a miRNA that down-regulates the early phase viral protein T-antigen and promotes viral latency\u2014could be detected and quantified by digital droplet PCR (ddPCR) in urine of 25 Natalizumab-treated MS patients. A 24-month study was designed: baseline, before the first dose of Natalizumab, and after 1 (T1), 12 (T12) and 24 months (T24) of therapy. miR-J1-5p was detected in urine of 7\/25 MS patients (28%); detection was possible in three cases at T24, in two cases at T12, in one case at T1 and T12, and in the last case at baseline and T1. Two of these patients were seronegative for JCPyV Ab, and viral DNA was never found in either urine or blood. To note, only in one case miR-J1-5p was detected before initiation of Natalizumab. These results suggest that the measurement of miR-J1-5p in urine, could be a biomarker to monitor JCPyV infection and to better identify the possible risk of developing PML in Natalizumab-treated MS patients.<\/jats:p>","DOI":"10.3390\/v13030468","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T02:51:48Z","timestamp":1615776708000},"page":"468","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-0645","authenticated-orcid":false,"given":"Simone","family":"Agostini","sequence":"first","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-3623","authenticated-orcid":false,"given":"Roberta","family":"Mancuso","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Saul","family":"Costa","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Caputo","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Clerici","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","article-title":"Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy","volume":"1","author":"Padgett","year":"1971","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/jvi.51.2.458-469.1984","article-title":"Human polyomavirus JC virus genome","volume":"51","author":"Frisque","year":"1984","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/jgv.0.000839","article-title":"ICTV Virus Taxonomy Profile: Polyomaviridae","volume":"98","author":"Moens","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature03576","article-title":"SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells","volume":"435","author":"Sullivan","year":"2005","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2009.02.017","article-title":"Murine polyomavirus encodes a microRNA that cleaves early RNA transcripts but is not essential for experimental infection","volume":"387","author":"Sullivan","year":"2009","journal-title":"Virology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhang, S., Sroller, V., Zanwar, P., Chen, C.J., Halvorson, S.J., Ajami, N.J., Hecksel, C.W., Swain, J.L., Wong, C., and Sullivan, C.S. (2014). Viral microRNA effects on pathogenesis of polyomavirus SV40 infections in syrian golden hamsters. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003912"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature03049","article-title":"Processing of primary microRNAs by the microprocessor complex","volume":"432","author":"Denli","year":"2004","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1101\/gad.927801","article-title":"Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans","volume":"15","author":"Ketting","year":"2001","journal-title":"Genes Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/ng1793","article-title":"Viruses and microRNAs","volume":"38","author":"Cullen","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1038\/sj.onc.1209909","article-title":"Principles and effects of microRNA-mediated posttranscriptional gene regulation","volume":"25","author":"Engels","year":"2006","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9823","DOI":"10.1128\/JVI.01144-08","article-title":"Evolutionarily conserved function of a viral micro-RNA","volume":"82","author":"Seo","year":"2008","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Takahashi, K., Sato, Y., Sekizuka, T., Kuroda, M., Suzuki, T., Hasegawa, H., and Katano, H. (2020). High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008523"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chom.2011.01.008","article-title":"An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination","volume":"9","author":"Bauman","year":"2011","journal-title":"Cell. Host. Microbe."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/13550289509113966","article-title":"Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA","volume":"1","author":"Trowbridge","year":"1995","journal-title":"J. Neurovirol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/13550280601009553","article-title":"JC virus T\u2019135, T\u2019136 and T\u2019165 proteins interact with cellular p107 and p130 in vivo and influecne viral transformation potential","volume":"12","author":"Bollag","year":"2006","journal-title":"J. Neurovirol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1002\/jcp.26219","article-title":"Discovery and characterization of novel trans-spliced products of human polyoma JC virus late transcripts from PML patients","volume":"233","author":"Saribas","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1002\/jcp.27715","article-title":"Expression of novel proteins by polyomaviruses and recent advances in the structural and functional features of agnoprotein of JC virus, BK virus, and simian virus 40","volume":"234","author":"Saribas","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/jcm.35.5.1255-1257.1997","article-title":"Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains","volume":"35","author":"Kitamura","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fonc.2019.00711","article-title":"Human polyomavirus JCPyV and its role in progressive multifocal leukoencephalopathy and oncogenesis","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_21","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin\u2019s disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/01.WNL.0000081306.86961.33","article-title":"Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual","volume":"61","author":"Corey","year":"2003","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","article-title":"The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans","volume":"111","author":"Zohren","year":"2008","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Clerico, M., Artusi, C.A., Di Liberto, A., Rolla, S., Bardina, V., Barbero, P., De Mercanti, S.F., and Durelli, L. (2017). Natalizuamb in Mutiple Sclerosis: Long-term management. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18050940"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study","volume":"83","author":"Goodman","year":"2014","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Butzkueven, H., Trojano, M., Kappos, L., Spelman, T., Wiendl, H., Rosales, K., Su, R., Licata, S., Ho, P.R., and Campbell, N. (2020). Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP). Mult. Scler., 1352458520917925.","DOI":"10.1177\/1352458520917925"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multiofcal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Linda","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: Updated reccomendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.autrev.2018.09.012","article-title":"A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis","volume":"18","author":"Sellner","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.0000000000002330","article-title":"Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay","volume":"86","author":"Stobbe","year":"2016","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1743-422X-11-158","article-title":"Viral miRNAs in plasma and urine divulge JC polyomavirus infection","volume":"11","author":"Lagatie","year":"2014","journal-title":"Virol. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2015.06.104","article-title":"The JCPYV DNA load inversely correlates with the viral microRNA expression in blood and cerebrospinal fluid of patients at risk of PML","volume":"70","author":"Rocca","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcv.2018.02.007","article-title":"BK polyomavirus microRNA expression and sequence variation in polyomavirus-associated nephropathy","volume":"102","author":"Virtanen","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revision to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1479-5876-10-248","article-title":"JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients","volume":"10","author":"Mancuso","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1177\/1352458514538111","article-title":"Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study","volume":"20","author":"Mancuso","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13365-014-0249-3","article-title":"Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM\/TSP patients and identification of viral mutations","volume":"20","author":"Brunetto","year":"2014","journal-title":"J. Neurovirol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1007\/s11033-020-05862-0","article-title":"COS-7 cells are a cellular model to monitor Polyomavirus JC miR-J1-5p expression","volume":"47","author":"Agostini","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","article-title":"Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"14","author":"Faulkner","year":"2015","journal-title":"Expert. Opin. Druf. Saf."},{"key":"ref_43","first-page":"1014","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult. Slcer."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2020.1763304","article-title":"An evaluation of dymethil fumarate for the treatment of relapsing remitting multiple sclerosis","volume":"21","author":"Carter","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","article-title":"JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab","volume":"68","author":"Ryschkewitsch","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcp.25056","article-title":"MicroRNA as biomarkers and diagnostics","volume":"231","author":"Wang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Condrat, C.E., Thompson, D.C., Barbu, M.G., Bugnar, O.L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiou, S.M., and Voinea, S.C. (2020). miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells, 9.","DOI":"10.3390\/cells9020276"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1055-9965.EPI-15-0289","article-title":"MicroRNA biomarker discovery and high-throughput DNA sequencing are possible using long-term archived serum samples","volume":"24","author":"Rounge","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2217\/bmm.13.44","article-title":"Stability of miRNA in human urine supports its biomarker potential","volume":"7","author":"Mall","year":"2013","journal-title":"Biomark. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3389\/fmicb.2020.01197","article-title":"MicroRNA biomarkers for infectious diseases: From basic research to biosensing","volume":"11","author":"Tribolet","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2015.01.019","article-title":"Expression of BKV and JCV encoded microRNA in human cerebrospinal fluid.; plasma and urine","volume":"65","author":"Pietila","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s13365-015-0325-3","article-title":"Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy","volume":"21","author":"Giovannelli","year":"2015","journal-title":"J. Neurovirol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13365-017-0560-x","article-title":"JCPyV microRNA in plasma correlates with JCPyV seropositive among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients","volume":"23","author":"Basnyat","year":"2017","journal-title":"J. Neurovirol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:34:41Z","timestamp":1760160881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["v13030468"],"URL":"https:\/\/doi.org\/10.3390\/v13030468","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}